We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Share News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Stocks-Factors to watch on March 15

Thu, 15th Mar 2018 05:25

March 15 (Reuters) - Britain's FTSE 100 index is seen opening 2points higher at 7,135 on Thursday, according to financial bookmakers. * SHELL: Royal Dutch Shell is close to bagging a deal to supplyHong Kong with liquefied natural gas (LNG), beating out major competitors forthe right to be the first company to supply LNG to the area. * GLENCORE: Glencore Plc, the world's biggest producer of cobalt,has agreed to sell around a third of its cobalt production over the next threeyears to Chinese battery recycler GEM Co Ltd, according to a filingby GEM on Wednesday. * BHP: BHP's Escondida copper mine in Chile, the world's largest,said on Wednesday that it has invited its powerful workers' union to start earlytalks on a new collective labor contract. * GOLD: Gold prices edged higher early Thursday and hovered near one-weekhighs hit in the previous session, as concerns over trade tensions weighed onshare markets. * OIL: Oil prices held steady on Thursday, supported by healthy globaldemand but capped by the relentless rise in U.S. production that is underminingefforts led by producer cartel OPEC to cut supplies and prop upmarkets. * EX-DIVS: Anglo American and Hammerson will trade withoutentitlement to their latest dividend pay-out on Thursday, trimming 1.37 pointsoff the FTSE 100 according to Reuters calculations. * The UK blue chip FTSE 100 index closed down 0.09 percent at7,132.69 points on Wednesday, as shares gave up early gains and finished innegative territory as points gained by Prudential and mining stocks wereoverturned by simmering fears of a global trade war that pushed Wall Street intothe red. * For more on the factors affecting European stocks, please click on: cpurl://apps.cp./cms/?pageId=livemarkets * UK CORPORATE DIARY: Phoenix Group Full Year 2017 Earnings Release OneSavings Bank Full Year 2017 Earnings Release Amryt Pharma PLC Q4 2017 Trading Statement Release Spirax-Sarco Engineering Full Year 2017 Earnings Release PV Crystalox Solar Full Year 2017 Earnings Release Old Mutual PLC Full Year 2017 Earnings Release Kier Group PLC Half Year 2018 Earnings Release Just Group PLC Full Year 2017 Earnings Release Savills Plc Full Year 2017 Earnings Release Cineworld Group plc Full Year 2017 Earnings Release TODAY'S UK PAPERS > Financial Times > Other business headlines Multimedia versions of Reuters Top News are now available for: * 3000 Xtra : visit http://topnews.session.rservices.com * For Top News : http://topnews.reuters.com (Reporting by Siju Varghese)
More News
3 Jun 2020 11:52

UK TRADING UPDATE SUMMARY: Integumen Kicks Off Covid-19 Skin Trials

UK TRADING UPDATE SUMMARY: Integumen Kicks Off Covid-19 Skin Trials

Read more
11 May 2020 12:19

Amryt Pharma Cheers Strong 2019 And Beats Expectations So Far In 2020

Amryt Pharma Cheers Strong 2019 And Beats Expectations So Far In 2020

Read more
23 Apr 2020 15:40

UK TRADING UPDATE SUMMARY: Braemar Says Oil Tankers Wanted For Storage

UK TRADING UPDATE SUMMARY: Braemar Says Oil Tankers Wanted For Storage

Read more
23 Mar 2020 19:01

Amryt Pharma Financially Strong, Revenue Rises More Double Digits

Amryt Pharma Financially Strong, Revenue Rises More Double Digits

Read more
19 Dec 2019 14:13

Amryt Pharma Shares Rise As It Cheers Aegerion Acquisition Synergies

Amryt Pharma Shares Rise As It Cheers Aegerion Acquisition Synergies

Read more
5 Nov 2019 11:09

Amryt Pharma upbeat on progress in first nine months of year

(Sharecast News) - Amryt Pharma updated the market on its trading update for the nine months ended 30 September on Tuesday, noting that it had completed the transaction to acquire Aegerion Pharmaceuticals on 24 September.

Read more
5 Nov 2019 10:23

Amryt Pharma Revenue Rises On Performance From Two New Assets

Amryt Pharma Revenue Rises On Performance From Two New Assets

Read more
1 Oct 2019 18:49

Amryt Pharma Skin Condition Drug Gets US FDA Fast Track Designation

Amryt Pharma Skin Condition Drug Gets US FDA Fast Track Designation

Read more
1 Oct 2019 15:08

Amryt gets FDA fast track for Oleogel-S10

(Sharecast News) - Biopharmaceutical company Amryt Pharma announced on Tuesday that the US Food and Drug Administration (FDA) has designated the investigation of 'AP101' - Oleogel-S10 - for the treatment of epidermolysis bullosa (EB) as a 'Fast Track' development programme.

Read more
30 Sep 2019 18:49

Amryt Pharma Loss Widens On Aegerion Deal Costs; Lojuxta Revenue Rises

Amryt Pharma Loss Widens On Aegerion Deal Costs; Lojuxta Revenue Rises

Read more
25 Sep 2019 12:24

Amryt Pharma Completes Combination With Aegerion Pharmaceuticals

Amryt Pharma Completes Combination With Aegerion Pharmaceuticals

Read more
24 Sep 2019 15:00

Amryt Pharma Shares Temporarily Suspended On Aegerion Buy

Amryt Pharma Shares Temporarily Suspended On Aegerion Buy

Read more
21 May 2019 12:35

Amryt Pharma Agrees To All-Paper Acquisition Of Aegerion (ALLISS)

LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said it has agreed the all-paper acquisition of Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics Inc, and intends to raise USD60

Read more
17 Apr 2019 11:17

Amryt Pharma Loss Narrows On Revenue From Cholesterol Drug Lojuxta

LONDON (Alliance News) - Amryt Pharma PLC on Wednesday said its annual loss narrowed as a result of increased revenue from its drug Lojuxta.The company's pretax loss shrank to EUR25.7

Read more
28 Feb 2019 14:39

Amryt gets approval to extend EASE trial to infants and children

(Sharecast News) - Orphan drug company Amryt Pharma updated the market on its phase 3 'EASE' trial for AP101 as a potential treatment for epidermolysis bullosa (EB) on Thursday, reporting that following an assessment by the trial's independent data monitoring committee, it could now enrol infants and children with EB between the ages of 21 days to four years in the trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.